The research details how neurons and glial cells utilize leucine-derived acetyl-coenzyme A (AcCoA) rather than canonical ...
Indeed, being obese not only increases the risk of developing a number of metabolic disorders, such as type 2 diabetes and hyperlipidemia, but is also associated with the occurrence of cardiovascular ...
A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...
Researchers from the University of Cambridge highlight new ways that neurons and many cell types use to sense nutrients - opening potential novel therapeutic avenues for disorders such as Alzheimer's ...
It has long been known that the protein TOR – Target of Rapamycin – controls cell growth and is involved in the development of diseases such as cancer and diabetes. Through a collaborative effort ...
BOSTON-- (BUSINESS WIRE)--PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, today announced the initiation of a Phase 2b study of its mechanistic target of ...
In a recent study published in Nature Metabolism, researchers conducted clinical studies on murine animals and humans to evaluate the impact of high protein intake on the amino acid-mammalian target ...
Novartis has offloaded two midphase mTORC1 inhibitors to PureTech Health. The agreement will see PureTech create a subsidiary, resTORbio, to move the assets into a phase 2b trial in diseases linked to ...
Am J Health Syst Pharm. 2010;67(24):2095-2106. The second mTOR complex, mTORC2, contains mTOR, mLST8, and several unique proteins, including rictor (rapamycin-insensitive companion of mTOR). Rapamycin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results